Author Archives: Wilmer Balmocena

September 11, 2020
In The News

[Korea Biomedical Review] GC said that it has partnered with Atomwise, a U.S. artificial intelligence-based drug development firm, to discover a new treatment candidate for hemophilia.

Read Article
September 9, 2020
In The News

[BioSpace]  Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross Corporation, to discover and develop novel hemophilia therapies. GC Pharma is a pioneer in vaccines and protein therapeutics and has long been dedicated to […]

Read Article
September 8, 2020
FeaturedPress Release

The partnership will develop new drug programs that advance GC Pharma’s global leadership in hemophilia and additional disease areas SAN FRANCISCO & YONGIN, South Korea–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross […]

Read Article
September 5, 2020
Broadcast

[Cheddar] Abraham Heifets, Co-founder & CEO of Atomwise joins Cheddar to discuss the company’s recent funding round and it’s coronavirus-related projects.

Read Article
August 27, 2020
In The News

[Nanalyze] Just a few weeks ago, Atomwise closed a $123 million Series B bringing their total funding so far to just over $174 million. The recent financing round includes new backing from two top-10 global insurance companies. Other notable investors include names like Monsanto, Tencent, Baidu Ventures, Khosla Ventures, Draper Associates, and OS Fund. The fresh […]

Read Article
August 25, 2020
In The News

[Analytics Insight] In recent years, the growing crops of startups that leverage artificial intelligence and other advanced technologies have ascended dramatically. As a result, the VC funding and investments in these startups are becoming historically strong year over year. Despite slow VC deals due to the COVID-19 crisis this year, the interest in AI funding is seeing a sustained […]

Read Article